MedTrace Logo

Study of DMXAA (Now Known as ASA404) in Solid Tumors

NCT00863733 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2009-03-18

No results posted yet for this study

Summary

This is a phase I study aimed at identifying safe doses of DMXAA in patients with solid tumors.

Conditions

Interventions

DRUG

DMXAA

Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2

Sponsors & Collaborators

Principal Investigators

  • Dr Paul Thompson · Auckland Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-05-31
Primary Completion
2000-03-31
Completion
2000-03-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00863733 on ClinicalTrials.gov